The Story Behind the Development of NexVax2 |
X You may need to Reload the page to make it work correctly.

The Story Behind the Development of NexVax2


Celiac disease research needs you!

Opt-in to stay up-to-date on the latest news.

Yes, I want to advance research No, I'd prefer not to Don't show me this again

ImmusanT's Chief Scientific Officer, Dr. Bob Anderson, discusses the development of the potential vaccine for celiac disease.

You may have heard of Nexvax2, the “celiac vaccine” currently undergoing clinical trials in the US and around the world. It’s an exciting breakthrough, and one that has been more than 20 years in the making.

To offer some perspective, Bob Anderson, MBChB, PhD, FRACP, Chief Scientific Officer at ImmunsanT, Inc, the pharmaceutical company behind NexVax2, wrote an article explaining the history and research findings that led to the development of this potential vaccine.

To get a glimpse of the process that led scientists to where they are today, read:

Transforming celiac disease from a digestive disease to an immune disease: and restoring tolerance to gluten in celiac disease


Advertise with us

  • Gluten Detective
  • Better bread. Better you. Schar's gluten-free bread.
  • Cravings Fulfilled Gluten-Free
  • Gluten-Free Resource Directory
  • Look for the Beyond Celiac logo and shop gluten-free with confidence.